|
US1910220A
(en)
*
|
1931-10-21 |
1933-05-23 |
Kremser Alois |
Mechanically operated gate
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU675916B2
(en)
|
1991-06-14 |
1997-02-27 |
Genentech Inc. |
Method for making humanized antibodies
|
|
DE69432815T2
(de)
|
1993-03-19 |
2003-12-11 |
The Johns Hopkins University School Of Medicine, Baltimore |
Wachstumsfaktor-8
|
|
US5994618A
(en)
|
1997-02-05 |
1999-11-30 |
Johns Hopkins University School Of Medicine |
Growth differentiation factor-8 transgenic mice
|
|
EP1075272B1
(en)
|
1998-05-06 |
2009-07-15 |
Metamorphix, Inc. |
Methods for treating diabetes by inhibiting gdf-8
|
|
US6927044B2
(en)
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
|
US7070784B1
(en)
|
1999-07-20 |
2006-07-04 |
Pharmexa A/S |
Method for down-regulating GDF-8 activity using immunogenic GDF-8 analogues
|
|
US6670140B2
(en)
|
2001-03-06 |
2003-12-30 |
The Procter & Gamble Company |
Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
US20040101920A1
(en)
|
2002-11-01 |
2004-05-27 |
Czeslaw Radziejewski |
Modification assisted profiling (MAP) methodology
|
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
|
UA85055C2
(ru)
|
2003-06-02 |
2008-12-25 |
Уайт |
Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
|
|
RU2422460C2
(ru)
|
2003-12-31 |
2011-06-27 |
Шеринг-Плоу Лтд. |
Выделенный пептид, обладающий специфической связывающей анти-gdf-8 антитело активностью, выделенная молекула нуклеиновой кислоты, вектор экспрессии, клетка-хозяин, способ получения пептида, вакцинная композиция и способ вызывания иммунного ответа анти-gdf-8, способ скрининга для отбора анти-gdf-8 антитела и способ понижающего регулирования активности gdf-8 у животного
|
|
US7456149B2
(en)
|
2004-03-02 |
2008-11-25 |
Acceleron Pharma, Inc. |
ALK7 and myostatin inhibitors and uses thereof
|
|
EP1733041B1
(en)
|
2004-03-23 |
2012-05-09 |
Eli Lilly & Company |
Anti-myostatin antibodies
|
|
EP1740946B1
(en)
|
2004-04-20 |
2013-11-06 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
WO2006020884A2
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
EA201100642A1
(ru)
|
2005-04-25 |
2011-12-30 |
Пфайзер Инк. |
Антитела к миостатину
|
|
KR101443050B1
(ko)
|
2005-05-06 |
2014-09-22 |
지모제넥틱스, 인코포레이티드 |
Ｉｌ-31 단클론성 항체 및 사용법
|
|
EP1773041A1
(en)
|
2005-07-21 |
2007-04-11 |
Chao-Hung Wu |
Audio/video data transmission system using the internet to interconnect telephones
|
|
US7888486B2
(en)
|
2005-08-19 |
2011-02-15 |
Wyeth Llc |
Antagonist antibodies against GDF-8
|
|
CN101277976B
(zh)
|
2005-10-06 |
2012-04-11 |
伊莱利利公司 |
抗肌抑制素抗体
|
|
UA92504C2
(en)
*
|
2005-10-12 |
2010-11-10 |
Эли Лилли Энд Компани |
Anti-myostatin monoclonal antibody
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
JP2009518422A
(ja)
|
2005-12-06 |
2009-05-07 |
アムジェン インコーポレイテッド |
ミオスタチン・アンタゴニストの使用
|
|
SI2374818T1
(sl)
|
2006-06-02 |
2013-03-29 |
Regeneron Pharmaceuticals, Inc. |
Visokoafinitetna protitelesa za humani IL-6 receptor
|
|
CA2693378C
(en)
|
2006-08-03 |
2020-04-14 |
Orico Limited |
Myostatin antagonists
|
|
WO2008030706A2
(en)
|
2006-09-05 |
2008-03-13 |
Eli Lilly And Company |
Anti-myostatin antibodies
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
TW201718635A
(zh)
|
2007-03-06 |
2017-06-01 |
安美基公司 |
變異之活動素受體多肽及其用途
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
EA022912B1
(ru)
|
2007-11-05 |
2016-03-31 |
Новартис Аг |
Производные 4-бензиламино-1-карбоксиацилпиперидина как ингибиторы бпхэ (белка-переносчика холестерилового эфира), применимые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
|
|
TW201919685A
(zh)
|
2008-08-14 |
2019-06-01 |
美商艾瑟勒朗法瑪公司 |
使用ｇｄｆ阱以增加紅血球水平
|
|
TW201029662A
(en)
*
|
2008-12-19 |
2010-08-16 |
Glaxo Group Ltd |
Novel antigen binding proteins
|
|
CA2749544A1
(en)
|
2009-01-13 |
2010-07-22 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
EP3275900A1
(en)
|
2009-04-27 |
2018-01-31 |
Novartis AG |
Compositions and methods for increasing muscle growth
|
|
MY199658A
(en)
|
2009-06-26 |
2023-11-14 |
Regeneron Pharma |
Readily isolated bispecific antibodies with native immunoglobulin format
|
|
EP2501400B1
(en)
|
2009-11-17 |
2017-11-01 |
Acceleron Pharma, Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
JO3340B1
(ar)
|
2010-05-26 |
2019-03-13 |
Regeneron Pharma |
مضادات حيوية لـعامل تمايز النمو 8 البشري
|
|
AR081556A1
(es)
|
2010-06-03 |
2012-10-03 |
Glaxo Group Ltd |
Proteinas de union al antigeno humanizadas
|
|
JP2013537425A
(ja)
|
2010-08-16 |
2013-10-03 |
アムジエン・インコーポレーテツド |
ミオスタチンに結合するポリペプチド、組成物および方法
|
|
AU2011326586A1
(en)
|
2010-11-08 |
2013-05-30 |
Acceleron Pharma, Inc. |
ActRIIA binding agents and uses thereof
|
|
KR102316283B1
(ko)
|
2011-05-16 |
2021-10-21 |
젠자임 코포레이션 |
메토트렉세이트를 이용한 면역 관용의 유도
|
|
WO2013074557A1
(en)
|
2011-11-14 |
2013-05-23 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
|
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
|
AU2013276131B2
(en)
*
|
2012-06-15 |
2017-08-24 |
Pfizer Inc. |
Improved antagonist antibodies against GDF-8 and uses therefor
|
|
WO2014022540A1
(en)
|
2012-08-02 |
2014-02-06 |
Regeneron Pharmaceuticals, Inc. |
Multivalent antigen-binding proteins
|
|
SG10201706148WA
(en)
|
2013-02-01 |
2017-08-30 |
Santa Maria Biotherapeutics Inc |
Administration of an anti-activin-a compound to a subject
|
|
TWI655207B
(zh)
|
2013-07-30 |
2019-04-01 |
再生元醫藥公司 |
抗活化素ａ之抗體及其用途
|
|
CA2918300A1
(en)
*
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
|
US20160075772A1
(en)
|
2014-09-12 |
2016-03-17 |
Regeneron Pharmaceuticals, Inc. |
Treatment of Fibrodysplasia Ossificans Progressiva
|
|
KR20170135967A
(ko)
|
2015-04-15 |
2017-12-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
|
|
US20180008672A1
(en)
|
2016-07-08 |
2018-01-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
|
|
CN111787981B
(zh)
|
2018-03-01 |
2025-12-30 |
瑞泽恩制药公司 |
增加肌肉量和减少脂肪量的方法
|